A phase III, double-blind, controlled, multicentric randomized study, designed to evaluate the immunogenicity and reactogenicity of the combined hepatitis A/hepatitis B preservative-free thimerosal-free vaccine as compared to the combined hepatitis A/hepatitis B vaccine with preservative, administered according to a 3-dose schedule (0, 1, 6 months) to healthy adults aged 18 years or older

Name: A phase III, double-blind, controlled, multicentric randomized study, designed to evaluate the immunogenicity and reactogenicity of the combined hepatitis A/hepatitis B preservative-free thimerosal-free vaccine as compared to the combined hepatitis A/hepatitis B vaccine with preservative, administered according to a 3-dose schedule (0, 1, 6 months) to healthy adults aged 18 years or older
Creator: GlaxoSmithKline
Keywords: Conditions: Hepatitis A, Conditions: Hepatitis B, Interventions: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine, 3. Good health

GlaxoSmithKline

Found an issue? Give us feedback

Vivliarrow_drop_down

Vivli

Dataset . 2018

Data sources: Datacite

A phase III, double-blind, controlled, multicentric randomized study, designed to evaluate the immunogenicity and reactogenicity of the combined hepatitis A/hepatitis B preservative-free thimerosal-free vaccine as compared to the combined hepatitis A/hepatitis B vaccine with preservative, administered according to a 3-dose schedule (0, 1, 6 months) to healthy adults aged 18 years or older

Research datakeyboard_double_arrow_right Dataset 01 Jan 2018Embargo end date: 01 Jan 2018 English Publisher:Vivli

Authors: GlaxoSmithKline;

doi: 10.25934/00001660

A phase III, double-blind, controlled, multicentric randomized study, designed to evaluate the immunogenicity and reactogenicity of the combined hepatitis A/hepatitis B preservative-free thimerosal-free vaccine as compared to the combined hepatitis A/hepatitis B vaccine with preservative, administered according to a 3-dose schedule (0, 1, 6 months) to healthy adults aged 18 years or older

- Summary
- Subjects
- Related research
  (3)
- Metrics

Abstract

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.

Keywords

Conditions: Hepatitis A, Conditions: Hepatitis B, Interventions: Hepatitis A (Inactivated), Hepatitis B (Recombinant) Vaccine

3 Research products, page 1 of 1

Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine
1999IsAmongTopNSimilarDocuments
Safety and Immunogenicity of a Combined Hepatitis A and Hepatitis B Vaccine in Young Healthy Adults
1996IsAmongTopNSimilarDocuments
Production of antibody to hepatitis A virus and hepatitis B surface antigen measured after combined hepatitis A/ hepatitis B vaccination in 242 adult volunteers
1998IsAmongTopNSimilarDocuments

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average